Generic Qvar RediHaler Availability
Last updated on Dec 12, 2024.
Qvar RediHaler is a brand name of beclomethasone, approved by the FDA in the following formulation(s):
QVAR REDIHALER (beclomethasone dipropionate - aerosol, metered;inhalation)
-
Manufacturer: NORTON WATERFORD
Approval date: August 3, 2017
Strength(s): 0.04MG/INH [RLD], 0.08MG/INH [RLD]
Has a generic version of Qvar RediHaler been approved?
No. There is currently no therapeutically equivalent version of Qvar RediHaler available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Qvar RediHaler. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Dose counter for inhaler having a bore and shaft arrangement
Patent 10,022,509
Issued: July 17, 2018
Inventor(s): Walsh Declan & Fenlon Derek & Kaar Simon & Hazenberg Jan Geert & Buck Daniel & Clancy Paul & Uschold Robert Charles & Karg Jeffrey A.A dose counter for an inhaler, the dose counter having a display tape arranged to be incrementally driven from a tape stock bobbin onto an incremental tape take-up drive shaft, the bobbin having an internal bore supported by and for rotation about a support shaft, at least one of the bore and support shaft having a protrusion which is resiliently biased into frictional engagement with the other of the bore and support shaft with longitudinally extending mutual frictional interaction.
Patent expiration dates:
- May 18, 2031✓
- May 18, 2031
-
Dose counters for inhalers, inhalers and methods of assembly thereof
Patent 10,022,510
Issued: July 17, 2018
Inventor(s): Walsh Declan & Fenlon Derek & Kaar Simon & Hazenberg Jan Geert & Buck Daniel & Clancy Paul & Uschold Robert Charles & Karg Jeffrey A.A tape system for a dose counter for an inhaler, the tape system having a main elongate tape structure, dosing indicia located on the main elongate tape structure, tape positioning indicia located on the main elongate tape structure, a tape size marker located on the main elongate tape structure indicating a number of dosing indicia on the tape, and priming indicia located on the main elongate tape structure, the priming indicia being located between the dosing indicia and one end of the tape.
Patent expiration dates:
- May 18, 2031✓
- May 18, 2031
-
Dose counter for inhaler and method for counting doses
Patent 10,086,156
Issued: October 2, 2018
Inventor(s): Walsh Declan & Fenlon Derek & Kaar Simon & Hazenberg Jan Geert & Buck Daniel & Clancy Paul & Uschold Robert Charles & Karg Jeffrey A.A dose counter for a metered dose inhaler includes an incremental counting system for counting doses. The incremental counting system has a main body, an actuator arranged to be driven in response to canister motion and to drive an incremental output member in response to canister motion. The actuator and incremental output member are configured to have predetermined canister fire and count configurations in a canister fire sequence. The canister fire configuration is determined by a position of the actuator relative to a datum at which the canister fires medicament and the count configuration is determined by a position of the actuator relative to the datum at which the incremental count system makes an incremental count. The actuator is arranged to reach a position in the count configuration at or after a position in the canister fire configuration.
Patent expiration dates:
- May 18, 2031✓
- May 18, 2031
-
Dose counter for inhaler having an anti-reverse rotation actuator
Patent 10,561,808
Issued: February 18, 2020
Inventor(s): Walsh Declan & Fenlon Derek & Kaar Simon & Hazenberg Jan Geert & Buck Daniel & Clancy Paul & Uschold Robert Charles & Karg Jeffrey A.A dose counter for an inhaler includes a counter display arranged to indicate dosage information, and a drive system arranged to move the counter display incrementally in a first direction from a first station to a second station in response to actuation input. A regulator is provided which is arranged to act upon the counter display at the first station to regulate motion of the counter display at the first station to incremental movements.
Patent expiration dates:
- January 1, 2032✓
- January 1, 2032
-
Dose counter for inhaler having an anti-reverse rotation actuator
Patent 10,695,512
Issued: June 30, 2020
Inventor(s): Walsh Declan & Fenlon Derek & Kaar Simon & Hazenberg Jan Geert & Buck Daniel & Clancy Paul & Uschold Robert Charles & Karg Jeffrey A.An inhaler includes a main body having a canister housing, a medicament canister retained in a central outlet port of the canister housing, and a dose counter having an actuation member for operation by movement of the medicament canister. The canister housing has an inner wall, and a first inner wall canister support formation extending inwardly from a main surface of the inner wall. The canister housing has a longitudinal axis X which passes through the center of the central outlet port. The first inner wall canister support formation, the actuation member, and the central outlet port lie in a common plane coincident with the longitudinal axis X such that the first inner wall canister support formation protects against unwanted actuation of the dose counter by reducing rocking of the medicament canister relative to the main body of the inhaler.
Patent expiration dates:
- May 18, 2031✓
- May 18, 2031
-
Breath actuated inhaler
Patent 10,792,447
Issued: October 6, 2020
Inventor(s): Walsh Declan & Prendergast Paul & Buck Daniel & Kent Trevor & Thompson Niall
Assignee(s): NORTON (WATERFORD) LIMITEDA breath actuated metered dose inhaler may include a canister fire system configured to fire a medicament containing canister in response to patient inhalation. The canister fire system may include a pneumatic force holding unit and having a rest configuration in which a metering valve of the canister is in a refill configuration; a prepared configuration in which a canister actuation force is retained by the pneumatic force holding unit and the canister fire system is actuatable by patient inhalation induced airflow; and a fire configuration in which the metering valve is in a dose delivery position. When in the prepared configuration, the force retained by the so pneumatic force holding unit may be reduced by less than about 6% over a period of 5 minutes, preferably less than about 3% over a period of 5 minutes.
Patent expiration dates:
- January 25, 2039✓
- January 25, 2039
-
Patent 11,395,888
Patent expiration dates:
- January 26, 2038✓
- January 26, 2038
-
Patent 11,395,889
Patent expiration dates:
- May 18, 2031✓
- May 18, 2031
-
Patent 11,559,637
Patent expiration dates:
- July 21, 2039✓
- July 21, 2039
-
Patent 11,583,643
Patent expiration dates:
- August 19, 2041✓
- August 19, 2041
-
Patent 11,793,953
Patent expiration dates:
- January 26, 2038✓
- January 26, 2038
-
Patent 11,865,247
Patent expiration dates:
- January 26, 2038✓
- January 26, 2038
-
Patent 11,896,759
Patent expiration dates:
- January 26, 2038✓
- January 26, 2038
-
Patent 11,957,832
Patent expiration dates:
- May 5, 2041✓
- May 5, 2041
-
Metered-dose inhaler
Patent 8,132,712
Issued: March 13, 2012
Inventor(s): Fenlon Derek
Assignee(s): Ivax Pharmaceuticals IrelandA metered dose inhaler dose counter, the counter includes: an actuator; a rotary gear wheel having a plurality of ratchet teeth; a driver for driving the rotary gear in a step-wise fashion in response to displacement of the actuator; a pawl that prevents reverse rotation of the rotary gear; and a display coupled to the rotary gear.
Patent expiration dates:
- September 7, 2028✓
- September 7, 2028
-
Inhaler
Patent 8,931,476
Issued: January 13, 2015
Inventor(s): Kaar Simon & Walsh Declan & Fenlon Derek & Buck Dan
Assignee(s): IVAX Pharmaceuticals IrelandAn inhaler, such as a breath-actuated metered-dose inhaler, for delivering medicament to a patient. The inhaler includes a housing for holding the medicament and having an air inlet and a medicament delivery port which together define an air flow path into which the medicament is dispensed. The air inlet includes an array of elongate apertures formed in the housing, the long sides of adjacent apertures facing each other. Each aperture is provided with a respective different opening in an outer surface of the housing. The opening of each aperture extends in two different planes such that, if at least a part of the opening is covered in one of the two different planes during inhalation by the patient, a void space is created between the cover and the aperture so as to provide an air flow path through the void space to the at least one aperture.
Patent expiration dates:
- July 17, 2031✓
- July 17, 2031
More about Qvar RediHaler (beclomethasone)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (188)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Drug class: inhaled corticosteroids
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
